Company: SCLXW
Filing Date: 2025-11-14
Form Type: 424B3
Source: 0001193125-25-283337
Chunk: 54

Company: Scilex Holding Co
Filing Date: 2025-11-14
Form: 424B3
Chunk 54
---
ido Royalty Purchase Agreement was $14.3 million and $6.8 million, respectively, recorded as a purchased revenue liability on the consolidated balance sheets. The Company incurred $0.2 million of issuance costs in connection with the ZTlido Royalty Purchase Agreement, which were included in the consolidated statement of operations for the year ended December 31, 2024. The following table summarizes the purchased revenue liability activity related to ZTlido Royalty Purchase Agreement (in thousands):

|                                                     | September 30, 
 2025          |        |   |
|:----------------------------------------------------|:--------------|-------:|:--|
| Ending Balance as of December 31, 2024              | $             |  6,800 |   |
| Repayment of purchased revenue liability            |               | (2,333 | ) |
| Change in fair value of purchased revenue liability |               |  9,833 |   |
| Ending Balance as of September 30, 2025             | $             | 14,300 |   |

Gloperba-Elyxyb Royalty Purchase Agreement On February 28, 2025 (the “Gloperba-Elyxyb Closing Date”), the Company entered into the Gloperba-Elyxyb Royalty Purchase Agreement with certain institutional investors (collectively, the “Gloperba-Elyxyb Royalty Investors”) and Oramed (together with the Gloperba-Elyxyb Royalty Investors, the “Gloperba-Elyxyb RPA Purchasers”). Pursuant to the Gloperba-Elyxyb Royalty Purchase Agreement, Scilex Pharma transferred to the Gloperba-Elyxyb RPA Purchasers the right to receive 4% of all aggregate net sales worldwide (the “Gloperba-Elyxyb Purchased Receivables”) with respect to Gloperba, Elyxyb, and any related, improved, successor, replacement and/or varying dosage forms of the foregoing (the “Gloperba-Elyxyb Covered Products”). In consideration of the Further Deferral and representing the “grant of the Royalty and Exclusive Rights” (as defined in the Term Sheet), during the period commencing on the Gloperba-Elyxyb Closing Date and expiring on the tenth anniversary of the Gloperba-Elyxyb Closing Date (the “Gloperba-Elyxyb Payment Term”), Scilex Pharma